DrugPatentWatch Database Preview
Mission Pharma Company Profile
What is the competitive landscape for MISSION PHARMA, and when can generic versions of MISSION PHARMA drugs launch?
MISSION PHARMA has fifteen approved drugs.
There are two US patents protecting MISSION PHARMA drugs.
There are ten patent family members on MISSION PHARMA drugs in seven countries and ten supplementary protection certificates in four countries.
Summary for Mission Pharma
| International Patents: | 10 |
| US Patents: | 2 |
| Tradenames: | 14 |
| Ingredients: | 12 |
| NDAs: | 15 |
Drugs and US Patents for Mission Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mission Pharmacal Co | CARBINOXAMINE MALEATE | carbinoxamine maleate | TABLET;ORAL | 090756-001 | May 27, 2011 | AA | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Mission Pharma | LITHOSTAT | acetohydroxamic acid | TABLET;ORAL | 018749-001 | May 31, 1983 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Mission Pharma | TINDAMAX | tinidazole | TABLET;ORAL | 021618-002 | May 17, 2004 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Mission Pharma | UROCIT-K | potassium citrate | TABLET, EXTENDED RELEASE;ORAL | 019071-002 | Aug 31, 1992 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Mission Pharma | TEXACORT | hydrocortisone | SOLUTION;TOPICAL | 081271-001 | Apr 17, 1992 | RX | No | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Mission Pharma | PREDNISOLONE SODIUM PHOSPHATE | prednisolone sodium phosphate | SOLUTION;ORAL | 091396-001 | Sep 13, 2010 | RX | No | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Mission Pharma Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2004035004 | ➤ Sign Up |
| European Patent Office | 2277503 | ➤ Sign Up |
| Canada | 2495886 | ➤ Sign Up |
| Australia | 2003284275 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 03075884 | ➤ Sign Up |
| Austria | 541575 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Mission Pharma Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 12/008 | Ireland | ➤ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| C0038 | France | ➤ Sign Up | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| C0026 | France | ➤ Sign Up | PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220 |
| C/GB12/028 | United Kingdom | ➤ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| C/GB08/020 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023. |
| C/GB95/010 | United Kingdom | ➤ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
